Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
9
5
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce